Parkman Healthcare Partners LLC Has $20.85 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Parkman Healthcare Partners LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 155.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,087,634 shares of the company's stock after buying an additional 662,634 shares during the quarter. Viridian Therapeutics comprises 2.8% of Parkman Healthcare Partners LLC's portfolio, making the stock its 8th biggest holding. Parkman Healthcare Partners LLC owned 1.37% of Viridian Therapeutics worth $20,850,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $26,000. Foresite Capital Management VI LLC bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $38,000. AlphaQuest LLC lifted its stake in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after buying an additional 1,516 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $164,000.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VRDN. The Goldman Sachs Group cut their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC cut their target price on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada cut their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $36.70.

Viridian Therapeutics Trading Down 0.9%

VRDN traded down $0.12 during mid-day trading on Monday, reaching $12.82. The stock had a trading volume of 192,304 shares, compared to its average volume of 982,424. The stock has a market capitalization of $1.05 billion, a P/E ratio of -2.97 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm's fifty day simple moving average is $13.41 and its two-hundred day simple moving average is $17.10.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue was up .0% on a year-over-year basis. On average, equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.